ALX Oncology Q3 net loss $51.0M; positive Phase 2 gastric cancer data; CEO change

ALX ONCOLOGY HOLDINGS INC

2023-Q3 EPS reported -$2.82

Q3 2023 GAAP net loss $51.0M ($1.24/diluted share) vs $35.3M ($0.87) in Q3 2022.
Cash, equivalents and investments $196.4M; runway into early 2026 including recent $63.2M offering proceeds.
Interim Phase 2 ASPEN-06: confirmed ORR 52% for evorpacept combo arm vs 22% for control in HER2+ gastric/GEJ cancer.
Leadership realignment: Jason Lettmann appointed CEO, Jaume Pons becomes President and CSO.
Closed public offering of common stock and pre-funded warrants in Oct 2023 for gross proceeds ~$63.2M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ALX ONCOLOGY HOLDINGS INC reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 13, 2023, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the third quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

ALX ONCOLOGY HOLDINGS INC filing history →

Source: SEC EDGAR

accession 0000950170-23-062903

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.